PDCD1 and melanoma: To investigate whether sClever-1 levels associate with response to immunotherapy, we obtained a dataset of lung carcinoma and melanoma patients with plasma sClever-1 levels measured before start of anti-PD-1 or anti-PD-L1 immunotherapy (Supplementary Table S3).